Anupam Rasayan India is expanding its footprint in pharmaceuticals and specialty chemicals through strategic acquisitions and pioneering flow chemistry, positioning for rapid growth and market diversification.
Anupam Rasayan India is moving deeper into pharmaceuticals and high-value speciality chemicals, with two acquisitions and a new process chemistry milestone that management says could shape its next phase of growth. The company expects to complete its planned purchase of Bliss GVS Pharma by the first half of September, after securing market regulator approval and finishing the open offer on August 10, according to a recent earnings call summary. At the same time, it is continuing to scale Jayhawk Fine Chemicals in the United States, where the business is already contributing a meaningful share of consolidated revenue.
The Bliss GVS transaction, first outlined in May, involves Anupam Rasayan taking up to a 43.3% stake for about ₹1,369.5 crore. Business Standard reported that the deal will be financed through roughly ₹300 crore of term debt, with the remainder coming from a non-controlling equity-linked instrument. Company executives say the acquisition should create a more integrated pharmaceutical platform spanning key starting materials and finished dosage forms, while also leaving room to improve capacity use across the business.
Jayhawk, meanwhile, is emerging as an important part of Anupam Rasayan’s portfolio. In the latest call, deputy chief financial officer Vishal Thakkar said the U.S. business accounted for about 20% to 22% of consolidated revenue in the quarter, with EBITDA margins of roughly 19% to 20%. He later added that Jayhawk’s quarterly revenue was about ₹145 crore, with EBITDA of around ₹30 crore. Earlier deal disclosures described Jayhawk as a roughly $150 million acquisition of a specialty chemicals maker with 2024 revenue of about $78 million and adjusted EBITDA of $15 million.
The company is also betting on chemistry that could open new markets. Management said Anupam Rasayan has commercialised ethyl trifluoroacetate, or ETFA, using flow chemistry, a continuous manufacturing technique that can improve safety, quality and environmental performance. The firm says it is the first in the world to do so and believes the addressable market for related molecules could be about $0.5 billion, with initial ambitions to capture 5% to 10% before potentially expanding further. ETFA has uses in pharmaceuticals, agrochemicals and electronics, including semiconductors.
Capital spending should remain relatively restrained after years of build-out. Thakkar said the company’s main capex cycle is largely complete and that annual spending for the core standalone business should be limited to roughly ₹70 crore to ₹80 crore, mainly for maintenance and repurposing. Jayhawk, he added, is unlevered and should not require support for its own capital needs. Management also pointed to a strong pipeline in semiconductors and said the business has secured a letter of intent with BASQUEVOLT, with commercial ramp-up expected from the second half of fiscal 2027.
For the near term, Anupam Rasayan is guiding for standalone EBITDA margins of 24% to 26% and consolidated margins of 22% to 24%, helped by a richer mix of performance materials and a recovering agrochemicals business. The company expects organic revenue growth of about 25%, plus or minus a couple of percentage points, with Jayhawk adding a further boost as its contribution was not in the prior-year base. Management said the larger question is no longer whether the portfolio can expand, but how quickly the new assets can be absorbed without straining the balance sheet or diluting returns.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
